12 May 2010

Dear [Name]

Final Appraisal Determination: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

I acknowledge your letter dated 26 April 2010 in response to my final scrutiny letter for the above appraisal. This letter will appear in the appeal papers but the appeals process is that that my final scrutiny response contains my final decisions on the grounds for appeal.

Yours sincerely

[Signature]

Appeal Committee Chair
National Institute for Health and Clinical Excellence